Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of survivin-loaded dendritic cell injection in newly diagnosed glioblastoma
CTR20261465Phase 2Active
- Sponsor
- Tricision Biotherapeutics
- Start
- Apr 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of survivin-loaded dendritic cell in glioblastoma (GBM), sponsored by Tricision Biotherapeutics. Started Apr 2026; status: active.
02
Drugs
survivin-loaded dendritic cell
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20261465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261465.